Royal Bank Of Canada Bio Line Rx Ltd. Transaction History

Royal Bank Of Canada

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.31 - $1.86 $2,602 - $3,695	-1,987 Reduced 96.79%	66 $0
Q1 2022 May 16, 2022	BUY	$1.46 - $2.18 $2,901 - $4,331	1,987 Added 3010.61%	2,053 $3,000
Q2 2021 Aug 16, 2021	BUY	$2.63 - $4.88 $173 - $322	66 New	66 $0

3.35M

46.5K

6.3K

Ticker BLRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,524,500
Market Cap $12.3M
Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.